[go: up one dir, main page]

CA2970717A1 - Compositions de (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1 (2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine -3-carboxamide pour preparations pharmaceutiques - Google Patents

Compositions de (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1 (2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine -3-carboxamide pour preparations pharmaceutiques Download PDF

Info

Publication number
CA2970717A1
CA2970717A1 CA2970717A CA2970717A CA2970717A1 CA 2970717 A1 CA2970717 A1 CA 2970717A1 CA 2970717 A CA2970717 A CA 2970717A CA 2970717 A CA2970717 A CA 2970717A CA 2970717 A1 CA2970717 A1 CA 2970717A1
Authority
CA
Canada
Prior art keywords
pyrrolidine
indazol
oxoethyl
methylthio
isopropoxypyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2970717A
Other languages
English (en)
Inventor
Pranav Gupta
Jason Wan
Scott T. Trzaska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2970717A1 publication Critical patent/CA2970717A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition comprenant du (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2(4-(4-(1-méthyl-1H-1,2,4-triazol-3-yl) phényl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoéthyl)-3-(méthylthio)pyrrolidine-3-carboxamide et de l'acétate succinate d'hypromellose pour des préparations pharmaceutiques, en particulier des préparations de gélules.
CA2970717A 2014-12-18 2015-12-14 Compositions de (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1 (2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine -3-carboxamide pour preparations pharmaceutiques Abandoned CA2970717A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093607P 2014-12-18 2014-12-18
US62/093,607 2014-12-18
PCT/US2015/065428 WO2016100147A1 (fr) 2014-12-18 2015-12-14 Compositions de (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-méthyl-1h-1,2,4-triazol-3-yl)phényl)-3,6-dihydropyridin-1 (2h)-yl)-2-oxoéthyl)-3-(méthylthio)pyrrolidine -3-carboxamide pour préparations pharmaceutiques

Publications (1)

Publication Number Publication Date
CA2970717A1 true CA2970717A1 (fr) 2016-06-23

Family

ID=56127413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2970717A Abandoned CA2970717A1 (fr) 2014-12-18 2015-12-14 Compositions de (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1 (2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine -3-carboxamide pour preparations pharmaceutiques

Country Status (11)

Country Link
US (3) US10577348B2 (fr)
EP (2) EP3233824B1 (fr)
JP (1) JP6657223B2 (fr)
KR (1) KR20170095972A (fr)
CN (2) CN111662272A (fr)
AU (1) AU2015362844B2 (fr)
BR (1) BR112017012547A2 (fr)
CA (1) CA2970717A1 (fr)
MX (1) MX2017008077A (fr)
RU (1) RU2017125322A (fr)
WO (1) WO2016100147A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014331628B2 (en) 2013-10-03 2018-08-30 Kura Oncology, Inc. Inhibitors of ERK and methods of use
US20180250232A1 (en) * 2015-09-03 2018-09-06 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
WO2021252316A1 (fr) * 2020-06-12 2021-12-16 Merck Sharp & Dohme Corp. Composition granulaire d'un inhibiteur d'erk et ses utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2003241925A1 (en) 2002-05-31 2003-12-19 Eisai R&D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
WO2006071644A1 (fr) * 2004-12-23 2006-07-06 Vertex Pharmaceuticals Incorporated Inhibiteurs selectifs de la proteine kinase erk et leurs utilisations
PT2054040E (pt) 2006-08-16 2011-06-30 Novartis Ag Método para produzir dispersões sólidas de compostos terapêuticos altamente cristalinos
JP5276676B2 (ja) * 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である化合物
US8586543B2 (en) 2008-08-19 2013-11-19 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
PT3006049T (pt) * 2013-06-03 2018-03-20 Shinetsu Chemical Co Composição para extrusão por fusão a quente e método para produzir um produto extrudido por fusão a quente

Also Published As

Publication number Publication date
EP3998258A1 (fr) 2022-05-18
BR112017012547A2 (pt) 2018-03-13
US10710982B2 (en) 2020-07-14
US11034673B2 (en) 2021-06-15
JP2017538720A (ja) 2017-12-28
KR20170095972A (ko) 2017-08-23
CN111662272A (zh) 2020-09-15
RU2017125322A3 (fr) 2019-02-28
JP6657223B2 (ja) 2020-03-04
US20200299266A1 (en) 2020-09-24
WO2016100147A1 (fr) 2016-06-23
US20170362202A1 (en) 2017-12-21
EP3233824B1 (fr) 2021-12-01
US20200181119A1 (en) 2020-06-11
EP3233824A4 (fr) 2018-05-30
EP3233824A1 (fr) 2017-10-25
US10577348B2 (en) 2020-03-03
CN107001322B (zh) 2020-07-28
RU2017125322A (ru) 2019-01-18
MX2017008077A (es) 2017-09-28
CN107001322A (zh) 2017-08-01
AU2015362844B2 (en) 2019-10-24
AU2015362844A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
CN113015521B (zh) 用于口服的包含氨基嘧啶衍生物或其盐的药物组合物
US11034673B2 (en) (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
WO2011064296A9 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
AU2011268335A1 (en) Asenapine maleate
HUP0402391A2 (hu) Telmisartan kristályos nátriumsója, eljárás előállítására és az azt tartalmazó gyógyszerkészítmények
US20240327415A1 (en) Multicomponent Complexes, Including Salts, Crystalline Forms, and Hydrates and Solvates of ENT1 Inhibitors
WO2025016385A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de ménine
WO2016005874A1 (fr) Procédé pour la préparation du régorafénib et ses formes cristallines
CN105026378B (zh) 不溶性药物的固体分散体及其制备方法
SI22092A (sl) Postopek za pripravo olmesartan medoksomila
US20140057928A1 (en) Solid state forms of a potent hcv inhibitor
US7750165B2 (en) Metaxalone polymorphs
WO2020225827A1 (fr) Nouveaux polymorphes de succinate de ribociclib
Lattmann et al. Pre-Clinical Evaluation of CCK2 Antagonist PNB-001 (4-Chloro-5-Hydroxy-1-Phenylethyl-5-Phenyl-1, 5-Dihydro-Pyrrol-2-One) Towards The Design For A First-In-Man Clinical Trial
CN106854164A (zh) 沙库比曲氨丁三醇盐的一种新晶型及其制备方法和用途
CN106146333A (zh) 沙库比曲钾盐的新晶型及其制备方法和用途
AU2013202838A1 (en) Solid state forms of a potent HCV inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201021

EEER Examination request

Effective date: 20201021

FZDE Discontinued

Effective date: 20230413

FZDE Discontinued

Effective date: 20230413